1. Recruitment Registry, Data Repository, and Tissue Repository Guidance
  2. Documenting Consent Electronically or for Remote Subjects Guidance
  3. Control of Test Articles Used in Research Policy
  4. Review of FDA-Regulated Research Policy
  5. Emergency Use of Test Articles and of Humanitarian Use Devices Policy
  6. Humanitarian Use Device Policy
  7. VA Research: Policy for IRB Review of Human Subjects Research that Falls Under VA Purview
  8. Policy and Guidance
  9. Guidance for X-Ray Radiation Use in Research Studies for Non-Healing Arts Purposes
  10. Remote Study Activities Guidance
  11. Do I need to get consent for my exempt study?
  12. Guidance on Research vs. Quality Improvement and Program Evaluation
  13. Sending or Receiving Specimens/Data/Images Guidance
  14. Guidance on Exemption: Not Human Subjects Research
  15. Application Type Guidance
  16. Emergency Use/Expanded Access
  17. Expanded Access of Investigational Medical Product Requests (Non-emergency)
  18. Emergency, Expanded Access for an Investigational Medical Product (One Patient)
  19. Information for New Investigators
  20. Expedited Change of Protocol Guidance
  21. Principal Investigator Changes and Personnel Updates Guidance
  22. Release of Grant Funds When IRB Review for a Study is Ceded to an External IRB
  23. Processing the Departure of a Principal Investigator Guidance
  24. Understanding the NIH Genomic Data Sharing (GDS) Policy
  25. Protocol Guidance
  26. Guidance on Making Editorial Changes to Subject-Facing Study Materials
  27. Scientific Review Requirement
  28. VA Research - Policy and Guidance
  29. Identification of Suicidality or Major Depression Guidance
  30. Training Grant, Umbrella Grant or Core Grant
  31. Case Reports and Case Series Guidance
  32. Letters of Cooperation for Non-UW Institutions/Organizations
  33. Family Education Rights and Privacy Act (FERPA) Guidance
  34. Scientific Review: UW Comprehensive Cancer Center (UWCCC) Protocol Review Monitoring Committee (PRMC)
  35. Clinically Relevant Information and Reporting Guidance
  36. Summary of Investigator Responsibilities
  37. Guidance on Exemption Categories under the Revised Common Rule
  38. Guidance for Completing IRB Applications for Recruitment Registries or Repositories that Store Data and/or Tissue
  39. Guidance on Research Involving Surveys, Interviews, and Focus Groups
  40. IRB QI/Program Evaluation Self-Certification Tool Guidance
  41. International Research Guidance
  42. Children as research participants: Pregnancy Status
  43. Key Personnel Guidance
  44. Using Specimens/Information from Decedents: The Common Rule and FDA Regulations
  45. Guidance for the Submission of Investigator's Drug Brochures (IDBs) and Package Inserts
  46. Guidance on the Five Year Renewal Policy and Replacement Studies in ARROW
  47. Use of Email for Research Purposes Guidance
  48. Identifiability Guidance
  49. Recruitment of Subjects with Status Relationship with the Research Team
  50. Guidance on FDA Regulation of Medical Mobile Apps
  51. Protocol Closure Guidance
  52. Guidance on Presenting Changes of Protocol to IRB
  53. Guidance Regarding Types of Supporting Materials that Require IRB Review and Approval
  54. Continuing Review: UW-Madison Purview Enrollment Guidance
  55. Investigational Software Guidance
  56. Genetic Information and Nondiscrimination Act (GINA) Guidance
  57. HIV Testing in Research Guidance
  58. Communicable Disease Guidance
  59. Vulnerable Populations Guidance
  60. MRIs and Pregnancy Status Guidance
  61. Audio Recordings, Video Recordings, Photographs Guidance
  62. What Happens After an Application Is Submitted to the Health Sciences or Minimal Risk IRB: Scientific Review
  63. Guidance Regarding Drug Shortages and Substitutions that Occur During the Conduct of Research Studies
  64. Data Safety Monitoring Plans (DSMP) Guidance
  65. Guidance Regarding Research that Involves the Collection of Information about Illegal Substance or Alcohol Abuse
  66. Outline of the Endorsement Process
  67. Guidance for Analysis Centers
  68. What Happens After a New Application Is Submitted to the Health Sciences or Minimal Risk IRB: IRB Administrative Review and IRB Pre-Review
  69. Timeframe for Submission of Changes of Protocol to the IRB
  70. Endorsement and Approval of VA Research
  71. Changes to Eliminate Immediate Hazards to Subjects Guidance
  72. Protocol Development Activities (PDA) Guidance
  73. Deception in Research Guidance
  74. Registry-Repository Overview Table
  75. Devices Implanted or Applied to Subjects Guidance